Development of an E. coli strain for cell‐free ADC manufacturing. Issue 1 (25th October 2021)

• Record Type: Journal Article
• Authors: Groff, Dan; Carlos, Nina A.; Chen, Rishard; Hanson, Jeffrey A.; Liang, Shengwen; Armstrong, Stephanie; Li, Xiaofan; Zhou, Sihong; Steiner, Alex; Hallam, Trevor J.; Yin, Gang
• Is Part Of: Biotechnology and bioengineering. Volume 119:Issue 1(2022)
• Page Start: 162
• Page End: 175
• Publication Date: 2021-10-25
• Subjects: antibody–drug conjugate (ADC) -- cell‐free protein synthesis -- nonnatural amino acids; Biotechnology -- Periodicals; Bioengineering -- Periodicals; 660.6
• DOI: 10.1002/bit.27961
• Languages: English
• ISSNs: 0006-3592

Abstract

Abstract: Recent advances in cell‐free protein synthesis have enabled the folding and assembly of full‐length antibodies at high titers with extracts from prokaryotic cells. Coupled with the facile engineering of the Escherichia coli translation machinery, E. coli based in vitro protein synthesis reactions have emerged as a leading source of IgG molecules with nonnatural amino acids incorporated at specific locations for producing homogeneous antibody–drug conjugates (ADCs). While this has been demonstrated with extract produced in batch fermentation mode, continuous extract fermentation would facilitate supplying material for large‐scale manufacturing of protein therapeutics. To accomplish this, the IgG‐folding chaperones DsbC and FkpA, and orthogonal tRNA for nonnatural amino acid production were integrated onto the chromosome with high strength constitutive promoters. This enabled co‐expression of all three factors at a consistently high level in the extract strain for the duration of a 5‐day continuous fermentation. Cell‐free protein synthesis reactions with extract produced from cells grown continuously yielded titers of IgG containing nonnatural amino acids above those from extract produced in batch fermentations. In addition, the quality of the synthesized IgGs and the potency of ADC produced with continuously fermented extract were indistinguishable from those produced with the batch extract. These experiments demonstrate that continuous fermentation of E. coli to produce extract for cell‐free protein synthesis is feasible and helps unlock the potential for cell‐free protein synthesis as a platform for biopharmaceutical production. Abstract : Through chromosomal engineering, an E. coli strain was generated that will facilitate large scale manufacturing of antibody drug conjugates (ADC) with cell free protein synthesis. This E. coli strain was capable of stable coexpression of FkpA, DsbC and o‐tRNA, three factors required for cell free ADC production over a multiday continuous fermentation.